TOUT
发表于 2025-3-21 16:07:31
书目名称Diagnosis and Management of Myelodysplastic Syndromes影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0270575<br><br> <br><br>书目名称Diagnosis and Management of Myelodysplastic Syndromes影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0270575<br><br> <br><br>书目名称Diagnosis and Management of Myelodysplastic Syndromes网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0270575<br><br> <br><br>书目名称Diagnosis and Management of Myelodysplastic Syndromes网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0270575<br><br> <br><br>书目名称Diagnosis and Management of Myelodysplastic Syndromes被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0270575<br><br> <br><br>书目名称Diagnosis and Management of Myelodysplastic Syndromes被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0270575<br><br> <br><br>书目名称Diagnosis and Management of Myelodysplastic Syndromes年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0270575<br><br> <br><br>书目名称Diagnosis and Management of Myelodysplastic Syndromes年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0270575<br><br> <br><br>书目名称Diagnosis and Management of Myelodysplastic Syndromes读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0270575<br><br> <br><br>书目名称Diagnosis and Management of Myelodysplastic Syndromes读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0270575<br><br> <br><br>
Peculate
发表于 2025-3-21 22:01:44
http://reply.papertrans.cn/28/2706/270575/270575_2.png
Digest
发表于 2025-3-22 03:11:47
http://reply.papertrans.cn/28/2706/270575/270575_3.png
synchronous
发表于 2025-3-22 06:01:57
http://reply.papertrans.cn/28/2706/270575/270575_4.png
Creditee
发表于 2025-3-22 08:43:36
http://reply.papertrans.cn/28/2706/270575/270575_5.png
CLAM
发表于 2025-3-22 13:03:04
MDS Mimics Including CHIP, ICUS, and CCUSns or findings of low specificity. There exist several MDS “mimics” that share findings with MDS but are caused by more benign conditions, other neoplasms, or less well-characterized pre-malignant states. Vitamin and iron deficiencies need to be excluded along with autoimmune conditions, medication
CLAM
发表于 2025-3-22 20:39:41
Prognostic Models in Myelodysplastic Syndromestools that take both patient (e.g., age, comorbidities) and disease characteristics (e.g., blast percentage, degree of cytopenias) into account have been developed and are the basis of clinical trial enrollment, patient counseling, and treatment recommendations. Among these clinical-pathologic scori
咽下
发表于 2025-3-22 22:57:54
Treatment Algorithms for Lower-Risk Myelodysplastic Syndromeerized by a low risk of progression to AML, but often prominent anemia. Prognosis of those patients can however be worsened by the presence of myelofibrosis, somatic mutations (except SF3B1 and TET2), resistance to first- and second-line treatments, and comorbidities..Anemia is generally the predomi
DEAF
发表于 2025-3-23 03:23:03
Treatment Algorithms for Higher-Risk Diseasel care. While hypomethylating agents (HMAs) have proven clinical and survival benefit in these patients, the only curative treatment remains allogeneic hematopoietic stem cell transplant (HSCT). No regimen has clear superiority in relapsed or refractory higher-risk MDS, and clinical trials (particul
敲竹杠
发表于 2025-3-23 07:12:36
http://reply.papertrans.cn/28/2706/270575/270575_10.png